Back to Information Overview
TOKYO (June 1, 2017) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Mark Tennyson, “Amgen Astellas”) today announced that Steve Sugino has been appointed as the President and Representative Director of Amgen Astellas through resolution of board of directors held today. Mark Tennyson simultaneously resigns from AABP’s General Manager and Representative Director and becomes the Director of Value, Access, and Policy, Amgen Japan and Asia Pacific Region.
Biography of Steve Sugino
Vice President, Amgen Inc.
President & Representative Director, Amgen Astellas BioPharma
Steve Sugino became Vice President of Amgen Inc. and General Manager of Amgen Astellas BioPharma (Amgen Astellas) in April 2017. As of June 1, 2017, he has been appointed as the President and Representative Director of Amgen Astellas. Prior to this role, he worked over 20 years in the pharmaceutical industry where he held various roles of increasing responsibility in general management, sales and marketing, clinical development, business development and alliance management in both Japan and the US.
Sugino, a fourth generation of Japanese-American, graduated with a degree in Asian Studies from the University of California, Santa Barbara and started his career at the Bank of Tokyo in Japan before moving to Credit Suisse First Boston as an investment banker in both Tokyo and New York. At Eli Lilly, he held a global brand development role for the neuroscience portfolio and other neuroscience molecules, working out of the US headquarters. His last role at Eli Lilly was Vice President of US diabetes commercial. He led Sanofi Japan’s diabetes business. He was most recently Head of Asia Pacific, and President and Representative Director of Japan for Biogen where he was responsible for all aspects of Biogen’s operations across the Asia Pacific region and for the fully integrated Japan affiliate.
Amgen Astellas BioPharma K.K. Corporate Affairs (Tel: +81-3-5293-9694)